{
  "drug_name": "fludarabine",
  "nbk_id": "NBK606096",
  "url": "https://www.ncbi.nlm.nih.gov/books/NBK606096/",
  "scraped_at": "2026-01-11T15:29:32",
  "sections": {
    "clinical_significance": "Diagnosing the specific type of hemolytic anemia is crucial for tailoring effective management strategies and optimizing patient outcomes. Distinguishing between different etiologies, such as AIHA, alloimmune hemolytic anemia, and other forms of hemolysis, guides treatment decisions and interventions. Identifying whether the condition involves warm or cold antibody-mediated mechanisms in AIHA influences treatment selection. Warm AIHA, characterized by IgG-mediated hemolysis, typically responds well to initial treatment with glucocorticoids and rituximab, particularly in symptomatic patients.\n[3]\nConversely, cold AIHA, involving IgM antibodies and complement activation, may necessitate different therapeutic approaches, such as avoidance of cold exposure and, in severe cases, plasmapheresis or immunosuppressive therapy.\n\nIn symptomatic patients with cold agglutinin disease, whether or not a low-grade bone marrow lymphoproliferative disorder is detected, first-line treatment typically involves immunosuppressive therapy with rituximab monotherapy or a rituximab-bendamustine combination.\n[57]\nParoxysmal cold hemoglobinuria is managed similarly to cold AIHA to avoid cold exposure; however, the efficacy of glucocorticoids has not been established.\n[10]\nThe cornerstone of treatment in patients with DIIHA involves discontinuation of the offending medication. Symptomatic cases may benefit from glucocorticoid therapy.\n[58]\n[59]\nSevere and relapsing cases may require further therapies such as IVIG therapeutic plasma exchange and/or rituximab.\n\nDiagnosing alloimmune hemolytic anemia, particularly in the context of hemolytic disease of the newborn or hemolytic transfusion reactions, informs immediate management strategies. Identifying maternal antibodies targeting fetal RBCs, typically anti-D antibodies, allows for timely interventions, including intrauterine transfusions or postnatal treatments to mitigate complications such as hydrops fetalis and neonatal jaundice.\n[60]\nSimilarly, recognizing the presence of alloantibodies in hemolytic transfusion reactions prompts immediate cessation of transfusion and supportive care measures to prevent further hemolysis and life-threatening complications."
  }
}